PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
21159855-8	2011	Furthermore, pretreatment of ISEMF cells with the phosphatidylinositol 3 kinase (PI3K) inhibitors, LY294002 and wortmannin, abrogated the IGF-I mRNA response to GLP-2, as did overexpression of kinase-dead Akt.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	99-107	insulin-like growth factor 1	Mus musculus	138-143	
18718566-9	2008	The phosphatidyl inositol 3 kinase (PI3K) inhibitor LY294002 inhibited IGF-I-induced cell migration and wound healing.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	52-60	insulin-like growth factor 1	Mus musculus	71-76	
19855934-4	2009	Inhibition of the PI3K/Akt pathway with LY294002 or Wortmannin led to a significant decrease in IGF-I-induced AR phosphorylation and total AR protein expression.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	40-48	insulin-like growth factor 1	Mus musculus	96-101	
19855934-5	2009	Furthermore, IGF-I-induced AR mRNA and skeletal alpha-actin mRNA were blocked by LY294002 or Wortmannin.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	81-89	insulin-like growth factor 1	Mus musculus	13-18	
19855934-6	2009	Confocal images showed that IGF-I-induced AR translocation from cytosol to nucleus was inhibited significantly in response to treatment with LY294002 or Wortmannin.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	141-149	insulin-like growth factor 1	Mus musculus	28-33	
19657059-6	2009	To identify potential IGF-I signaling molecules, the phosphatidylinositol 3-kinase (PI3K) inhibitors wortmannin and LY-294002 were both found to markedly attenuate IGF-I activation of the 1.3-kb type IIb MyHC promoter.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	116-125	insulin-like growth factor 1	Mus musculus	22-27	
19657059-6	2009	To identify potential IGF-I signaling molecules, the phosphatidylinositol 3-kinase (PI3K) inhibitors wortmannin and LY-294002 were both found to markedly attenuate IGF-I activation of the 1.3-kb type IIb MyHC promoter.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	116-125	insulin-like growth factor 1	Mus musculus	164-169	
19246485-8	2009	The blockage of IGF-1 receptor phosphorylation and its downstream PI3K pathway by PPP or LY294002 dramatically reduced their AP activity and expression of pluripotent genes, such as Oct-4, Blimp1, and Nanog.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	89-97	insulin-like growth factor 1	Mus musculus	16-21	
18206295-5	2008	Akt/PKB activation by GnRH and IGF-1 was completely eliminated in the presence of the PI3-kinase inhibitor, LY 294002, but not in the presence of an Akt/PKB inhibitor.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	108-117	insulin-like growth factor 1	Mus musculus	31-36	
18797142-5	2008	When phosphatidylinositol 3-kinase (PI3K) pathway was inhibited by LY294002, the increase in collagen induced by ELF-EMF exposure was accelerated, however, the increase in collagen observed by IGF-I addition was suppressed.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	67-75	insulin-like growth factor 1	Mus musculus	193-198	
11500504-6	2001	Induction of myogenin by IGF-I and myotube formation were prevented by the phosphatidylinositol (PI) 3-kinase inhibitor, LY294002, even when included 2 days after growth factor addition, whereas expression of active PI 3-kinase could promote differentiation in the absence of IGF-I.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	121-129	insulin-like growth factor 1	Mus musculus	25-30	
16086373-10	2005	In further studies, the PI3K inhibitor, LY294002, significantly blocked IGF-1-mediated epidermal proliferation and skin tumor promotion in DMBA-initiated BK5.IGF-1 mice.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	40-48	insulin-like growth factor 1	Mus musculus	72-77	
16086373-10	2005	In further studies, the PI3K inhibitor, LY294002, significantly blocked IGF-1-mediated epidermal proliferation and skin tumor promotion in DMBA-initiated BK5.IGF-1 mice.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	40-48	insulin-like growth factor 1	Mus musculus	158-163	
15724079-8	2005	Treatment with 10(-7) M of the MAP kinase inhibitor PD098059 and 10(-5) M of the PI-3 kinase inhibitor LY294002 decreased IGF-I-induced BrdU-uptake in the endometrial stromal cells.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	103-111	insulin-like growth factor 1	Mus musculus	122-127	
11546773-5	2001	Insulin/IGF1-induced ubiquitination and degradation of IRS-2 was blocked by inhibitors of phosphatidylinositol 3-kinase (wortmannin or LY294002) or mTOR (rapamycin).	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	135-143	insulin-like growth factor 1	Mus musculus	8-12	
16787946-8	2006	Inhibition of PI 3-kinase by LY294002 produced strong and moderate reductions in IGF-I-stimulated P-Akt(Ser473) and P-Akt(Thr308), respectively.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	29-37	insulin-like growth factor 1	Mus musculus	81-86	
15971148-5	2005	LY294002 and wortmannin, inhibitors of phosphatidylinositol 3-kinase, significantly suppressed the IGF-I-induced alkaline phosphatase activity.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	0-8	insulin-like growth factor 1	Mus musculus	99-104	
15971148-6	2005	The phosphorylation of Akt induced by IGF-I was markedly reduced by LY294002 and wortmannin.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	68-76	insulin-like growth factor 1	Mus musculus	38-43	
11500504-6	2001	Induction of myogenin by IGF-I and myotube formation were prevented by the phosphatidylinositol (PI) 3-kinase inhibitor, LY294002, even when included 2 days after growth factor addition, whereas expression of active PI 3-kinase could promote differentiation in the absence of IGF-I.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	121-129	insulin-like growth factor 1	Mus musculus	276-281	
11500504-8	2001	The differentiation-promoting effects of IGF-I were mimicked by a modified membrane-targeted inducible Akt-1 (iAkt), and iAkt was able to stimulate differentiation of C2 myoblasts and primary mouse myoblasts incubated with otherwise inhibitory concentrations of LY294002.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	262-270	insulin-like growth factor 1	Mus musculus	41-46	
30130150-8	2018	The activity of a reporter construct containing the ABCA1 promoter was induced by IGF1, and this effect was blocked by LY294002, a specific inhibitor of phosphatidylinositol 3-kinase (PI3K).	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	119-127	insulin-like growth factor 1	Mus musculus	82-86	
10976992-7	2000	IGF-I was able to counteract the apoptotic stimulus of TNF-alpha and this was accompanied by the intranuclear translocation of PI 3-K. LY294002 inhibited both intranuclear translocation of PI 3-K and the rescuing effect of IGF-I.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	135-143	insulin-like growth factor 1	Mus musculus	0-5	
10976992-7	2000	IGF-I was able to counteract the apoptotic stimulus of TNF-alpha and this was accompanied by the intranuclear translocation of PI 3-K. LY294002 inhibited both intranuclear translocation of PI 3-K and the rescuing effect of IGF-I.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	135-143	insulin-like growth factor 1	Mus musculus	223-228	
10092673-7	1999	The pathway by which IGF-1 promotes neuronal survival and activation of NF-kappaB involves the phosphoinositol (PI) 3-kinase, because both effects of IGF-1 are blocked by LY294002 and wortmannin, two specific PI 3-kinase inhibitors.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	171-179	insulin-like growth factor 1	Mus musculus	21-26	
10092673-7	1999	The pathway by which IGF-1 promotes neuronal survival and activation of NF-kappaB involves the phosphoinositol (PI) 3-kinase, because both effects of IGF-1 are blocked by LY294002 and wortmannin, two specific PI 3-kinase inhibitors.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	171-179	insulin-like growth factor 1	Mus musculus	150-155	
34031457-6	2021	Pre-treatment with IGF-1 signal pathway specific inhibitors such as picropodophyllin, LY294002, and rapamycin attenuated EE induced myotube hypertrophy and MyHC isoform overexpression.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	86-94	insulin-like growth factor 1	Mus musculus	19-24	
31018166-8	2019	Regarding the inhibitory mechanism, we found that the level of AKT and p-AKT can be decreased by Dex and that Ly294002, the PI3K inhibitor, can block the reversal effect of IGF-1.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	110-118	insulin-like growth factor 1	Mus musculus	173-178	
10342860-9	1999	By comparison, the antiapoptotic effects of insulin-like growth factor I on germ cells in cultured fetal ovaries were significantly attenuated by cotreating ovaries with LY294002 (P < 0.05) but not with alpha-amanitin or cycloheximide (P > 0.05).	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	170-178	insulin-like growth factor 1	Mus musculus	44-72	
9927327-12	1999	Lastly, the antiapoptotic effects of SCF/LIF or IGF-I were almost entirely eliminated by cotreatment of fetal ovaries with either one of two inhibitors of phosphatidylinositol-3"-kinase (PI3K), LY294002 (5 microM) or wortmannin (50 nM), whereas cotreatment with an inhibitor of p70 S6 kinase (rapamycin, 25 ng/ml) was without effect.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	194-202	insulin-like growth factor 1	Mus musculus	48-53	
33724692-8	2021	Also, T3 increased the expression of IGF-1, and PI3K/Akt signalling in cardiomyocytes under H/R-induced injury, and that the protective effect of T3 against H/R-induced injury was blocked by the PI3K inhibitor LY294002.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	210-218	insulin-like growth factor 1	Mus musculus	37-42	
26146542-7	2015	In C2C12 myogenic cells, blocking the IGF1/PI3K/Akt pathway using LY294002 inhibitor reduced MSY3 phosphorylation levels resulting in its accumulation in the nuclei.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	66-74	insulin-like growth factor 1	Mus musculus	38-42	
27774572-7	2017	The protective effect of IGF-1 was reversed by PI3K inhibitors LY294002 and wortmannin as well as the Akt inhibitor VIII.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	63-71	insulin-like growth factor 1	Mus musculus	25-30	
24582811-11	2014	Specific inhibition of ERK1/2 by U0126 or PI3K by LY294002 reduced the IGF1-induced differentiation.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	50-58	insulin-like growth factor 1	Mus musculus	71-75	
24598112-8	2014	The IGF-I dose dependently increased the HIF-2alpha expression levels in AP(+)GSCs; and, the inhibition of IGF-IR by RNA interference (shIGF-IR) or LY294002 (PI3K inhibitor)/Rapamycin (mTOR inhibitor) effectively suppressed the IGF-I- and/or hypoxia-induced HIF-2alpha and Oct-4 expression, suggesting that the IGF-IR and its downstream Akt/mTOR signaling are involved in the IGF-I/hypoxia effects.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	148-156	insulin-like growth factor 1	Mus musculus	4-9	
25339702-7	2015	Inhibition of PI3-kinase (PI3-K) with LY294002 (20 muM) abrogates activation of ClC-K2 by IGF-1.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	38-46	insulin-like growth factor 1	Mus musculus	90-95	
22249904-6	2012	The IGF-1-induced osteoblast proliferation was mediated via both MAPK and Akt pathways because the IGF-1-mediated cell proliferation was blocked by U0126, an MEK/MAPK inhibitor, or LY294002, a PI3-kinase inhibitor.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	181-189	insulin-like growth factor 1	Mus musculus	4-9	
24580070-5	2014	PI3 inhibitors LY294002 and Wortmannin abolished the effect of IGF-1 on FoxO3a phosphorylation indicating that FoxO3a phosphorylation is mediated by PI3/Akt-1 pathway.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	15-23	insulin-like growth factor 1	Mus musculus	63-68	
22956516-8	2012	However, western blot analyses coupled with pretreatment of cells with the PI3K inhibitor LY294002 indicated that the synergistic effect of cAMP and IGF1 on transcript levels was due in part to cooperative increases in Akt phosphorylation.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	90-98	insulin-like growth factor 1	Mus musculus	149-153	
23472139-13	2013	AGEs treatment promoted the differentiation of 3T3-L1 preadipocytes and addition of AG1024, LY 294002 or Akt inhibitor attenuated the promoting effect of AGEs on adipogenesis, suggesting that IGF-1 receptor, PI3-Kinase and Akt are involved in the facilitation of adipogenesis by AGEs.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	92-101	insulin-like growth factor 1	Mus musculus	192-197	
22249904-6	2012	The IGF-1-induced osteoblast proliferation was mediated via both MAPK and Akt pathways because the IGF-1-mediated cell proliferation was blocked by U0126, an MEK/MAPK inhibitor, or LY294002, a PI3-kinase inhibitor.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	181-189	insulin-like growth factor 1	Mus musculus	99-104